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Background
The NAD
+-dependent family of sirtuin proteins
(SIRT1–7), is involved in cell apoptosis and senescence.
Salermide is a potent inhibitor of SIRT1 and SIRT2 and
can induce tumor-specific cell death in selected human
cell lines. In this study we investigated salermide’s apop-
totic effect in a wide range of other human cancer cell
lines and its antiproliferative potential in combination
with cisplatin.
Methods
Seven different cancer cell lines (SKOV-3, MKN45,
MKN28, N87, FaDu, NuLi1, Jurkat) were treated with
salermide (1 µM – 0.1 nM) for 24, 48, and 72 hours
and assessed for cell viability. Three cell lines (SKOV-3,
N87, Jurkat) were selected for combination therapy with
salermide and cisplatin (30 µM). In order to characterize
salermide’s proapoptotic pathway SIRT1, SIRT2, pAKt,
p53, acetyl-p53 and Nampt (nicotinamide phosphoribo-
syltransferase) were determined in SKOV-3 and Jurkat
cells by Western blotting.
Results
Salermide yielded greater dose-dependent apoptotic
effects in Jurkat, SKOV-3 and N87 cells than in the
other cell lines, with most potent effect after 48 h of
incubation. The anti-proliferative activity was associated
with a G0-G1 cell cycle arrest. SIRT1 and SIRT2 protein
were down-regulated after 48 h and 72 h. This was
accompanied by a down-regulation of pAKT, p53 and
Nampt. Acetyl-p53 levels were not consistent across cell
types. Cisplatin exerted synergistic effects with salermide
in all cell lines and reduced cell viability up to 50%.
Conclusions
Salermide-induced apoptosis is cell line-dependent and
more effective in slow-proliferating (SKOV-3) and
hematologic (Jurkat) cancer cells. The synergism with
cisplatin implies a potentiating effect of this sirtuin inhi-
bitor as add-on in clinical cancer therapy.
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